The nomination committee proposes changes to Scandinavian ChemoTech's board to strengthen the focus on commercialization
The nomination committee in Scandinavian ChemoTech AB ("ChemoTech") has decided to propose changes to the board to provide better conditions for, and create a clearer focus on, commercialization of the company's products.
After ChemoTech built a clinical platform and strategy in recent years to take the company's technology into areas such as deep-seated tumors and immunotherapy, the company is now entering a commercialization phase in earnest.
Against this background, the nomination committee nominates Robin Sukhia as the new chairman of the company's board. Robin has solid experience in supporting small and large Swedish companies from his current role as CEO and Secretary General of the Sweden-India Business Council. Robin also has a good knowledge of the capital market after working for a decade in the Swedish venture capital industry.
To supplement the board with a person who has global experience in product launches and commercialization of medical technology products as well as pharmaceutical products in North America and the Middle East, the nomination committee nominates the Canadian Nicolas Pepin as a new board member in the company.
Nicolas has had a career within Abbot Nutrition International for over 15 years and has worked for large pharmaceutical companies such as Pfizer, Smith & Nephew, Aventis Pharma and Hoechst Marion Roussel for 15 years. He has experience in marketing, commercial launches and innovation as well as sales to the private and professional healthcare market in areas such as nutrition, smoking cessation, wound care, diabetes, cardiology and oncology.
Lars Hedbys does not wish to run for re-election as a member and is making his seat available.
Martin Jerndal is making his place available as he wishes to focus on the family business, but has indicated that he still intends to be an active and long-term owner of ChemoTech.
"It has been intense, pleasant and very interesting election committee work before the annual general meeting. Board members and shareholders have been very positive and have given constructive answers to the questions in the interview work, and these constructive publications and information gathering in the conversations have led to the nominations that the nomination committee proposed. The nominations completely reflect how you want to see ChemoTech and its continued work to strengthen and drive the commercialization of ChemoTech's products going forward," says Roland Möller, chairman of the nomination committee.
For further information:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser: Redeye AB, Tel: +46 (0)8 - 121 576 90
E-mail:certifiedadviser@redeye.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.